Clinical trial
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal…
NCT00097955 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00097955 |
|---|---|
| Title | Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria |
| Official title | Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | aliskiren |
| Enrollment | 496 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Dec 2, 2004 |
| Last update posted | May 17, 2017 |
| Countries | Canada, Denmark, France, Germany, Greece, Italy, Netherlands, Romania, Russia, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: